Viral vaccines forge ahead

Jesitus, John
January 2008
Dermatology Times;Jan2008, Vol. 29 Issue 1, p40
Trade Publication
The article reports on the views of Stephen K. Tyring, professor of dermatology at the University of Texas Health Science Center in Houston, regarding the efficacy of viral vaccines such as the human papilloma virus (HPV) vaccine Gardasil. According to Tyring, the HPV vaccine continues to be effective in preventing external genital cancer, genital warts and cervical cancer. Moreover, Tyring claims that viral vaccine Zostavax is also proven safe and effective at preventing shingles.


Related Articles

  • Human papillomavirus vaccine risk and reality. MacDonald, Noni; Stanbrook, Matthew B.; Hébert, Paul C. // CMAJ: Canadian Medical Association Journal;9/9/2008, Vol. 179 Issue 6, p503 

    The authors reflect on the lack of participation of students in school-based human papillomavirus (HPV) vaccine programs in Ontario. They point out that only about 50% of students in the province decided to have the HPV vaccine. They stress that one reason for the reluctance to receive the...

  • A semi-qualitative study of attitudes to vaccinating adolescents against human papillomavirus without parental consent. Brabin, Loretta; Roberts, Stephen A.; Kitchener, Henry C. // BMC Public Health;2007, Vol. 7 Issue 1, p20 

    Background: The first vaccine to prevent human papillomavirus (HPV) and cervical cancer has been licensed, and in future, vaccination may be routinely offered to 10-14 year old girls. HPV is a sexually transmitted virus and some parents may refuse consent for vaccination. Under-16s in the UK...

  • CDC Adds Shingles Vaccine to List for Adults 60 Plus.  // Internal Medicine Alert;7/15/2008, Vol. 30 Issue 13, p1 

    The article provides information on Shingles vaccine which is added to the U.S. Centers for Disease Control and Prevention (CDC) list of vaccines recommended for adults 60 years and older.

  • Appendix 2: Model NRA Lot Release Certificate for recombinant human papillomavirus virus-like particle vaccines.  // WHO Technical Report Series;2016, Issue 999, p232 

    An appendix is presented of model NRA Lot Release Certificate for recombinant human papillomavirus virus-like particle vaccines from the World Health Organization Expert Committee on Biological Standardization.

  • Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine. Slade, Barbara A.; Leidel, Laura; Vellozzi, Claudia; Woo, Emily Jane; Wei Hua; Sutherland, Andrea; Izurieta, Hector S.; Ball, Robert; Miller, Nancy; Braun, M. Miles; Markowitz, Lauri E.; Iskander, John // JAMA: Journal of the American Medical Association;8/19/2009, Vol. 302 Issue 7, p750 

    The article focuses on a study which summarized data from the U.S. Vaccine Adverse Event Reporting System (VAERS) following receipt of recombinant human papillomavirus vaccine (qHPV). The qHPV reports received by VAERS from June 1, 2006 to December 31, 2008 were analyzed. A total of 12,424...

  • Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France. Riethmuller, Didier; Jacquard, Anne-Carole; St Guily, Jean Lacau; Aubin, François; Carcopino, Xavier; Pradat, Pierre; Dahlab, André; Prétet, Jean-Luc // BMC Public Health;2015, Vol. 15 Issue 1, p1 

    Background: Human Papillomavirus (HPV) infection is known to be associated with a number of conditions including cervical, vaginal, vulvar, penile, anal neoplasias and cancers, oropharynx cancers and genitals warts (GW). Two prophylactic vaccines are currently available: a bivalent vaccine...

  • Herpes zoster vax cost effective in older adults in Belgium?  // PharmacoEconomics & Outcomes News;1/7/2012, Issue 644, p6 

    The article discusses research study on the cost-effectiveness of the varicella zoster virus vaccine Zostavax against herpes zoster in adults aged over 60 years in Belgium. It references a study by J. Bilcke et al published in the November 24, 2011 issue of "Vaccine." The researchers have...

  • Herpes Zoster.  // Clinical Infectious Diseases;11/1/2006, Vol. 43 Issue 9, pvii 

    The article discusses the significance of vaccination in preventing the occurrence of herpes zoster and postherpetic neuralgia in older adults. Vaccination of adults aged beyond 60 years can help reduce the risk of herpes zoster. The advantage of taking vaccines can increase the survival rate of...

  • Grounds for Gardasil. Jesitus, John // Dermatology Times;Apr2007, Vol. 28 Issue 4, p1 

    The article reports that Merck & Co. Inc. has suspended its lobbying campaign to make its newly approved vaccine Gardasil mandatory for young girls in the U.S. According to Dr. Stephen K. Tyring, Gardasil is the first vaccine to protect against two strains of human papillovirus (HPV) that can...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics